|
|
|
Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a
biotechnology company focused on developing autologous cell
therapies for aesthetic, medical and scientific
applications. Fibrocell Science is committed to advancing
the scientific, medical and commercial potential of
autologous skin and tissue, as well its innovative cellular
processing technology and manufacturing excellence.
Fibrocell Therapy is an investigational autologous cell
therapy. In the Fibrocell Science patented process, a
patient's own natural fibroblasts are extracted, multiplied
and re-injected as personalized therapy to regenerate skin.
Fibroblasts are cells that contribute to the formation of
connective tissue fibers. The Fibrocell Therapy for
aesthetics, azficel-T, proposed brand name Laviv™ is
currently under review by the FDA for the treatment of
moderate to severe nasolabial fold wrinkles.
Fibrocell Science, Inc. is planning to continue studies for
additional aesthetic and therapeutic indications for its
Fibrocell Therapy, which is manufactured at a cGMP cell
therapy manufacturing facility at its headquarters in
Pennsylvania.
SAFE HARBOR
All statements contained on this site that are not based on
historical fact are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of
1995 and the provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. While management has based
any forward-looking statements contained herein on its
current expectations, the information on which such
expectations were based may change. These forward-looking
statements rely on a number of assumptions concerning future
events and are subject to a number of risks, uncertainties,
and other factors, many of which are outside of our control,
that could cause actual results to materially differ from
such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those
set forth under Item 1A "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31,
2008, as updated in "Item 1A. Risk Factors" in the Company's
Quarterly Reports on Form 10-Q. We operate in a highly
competitive and rapidly changing environment, thus new or
unforeseen risks may arise. Accordingly, investors should
not place any reliance on forward-looking statements as a
prediction of actual results. We disclaim any intention to,
and undertake no obligation to, update or revise any
forward-looking statements. Readers are also urged to
carefully review and consider the other various disclosures
in the Company's Annual Report on Form 10-K for the year
ended December 31, 2008, as well as other public filings
with the SEC since such date.
 
|
|
